Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB
[img] Other (Supplementary Data)
1MB

Item Type:Article
Title:Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription
Creators Name:Edelmann, J. and Holzmann, K. and Tausch, E. and Saunderson, E.A. and Jebaraj, B.M.C. and Steinbrecher, D. and Dolnik, A. and Blätte, T.J. and Landau, D.A. and Saub, J. and Estenfelder, S. and Ibach, S. and Cymbalista, F. and Leblond, V. and Delmer, A. and Bahlo, J. and Robrecht, S. and Fischer, K. and Goede, V. and Bullinger, L. and Wu, C.J. and Mertens, D. and Ficz, G. and Gribben, J.G. and Hallek, M. and Döhner, H. and Stilgenbauer, S.
Abstract:To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of TP53 aberrations, we comprehensively analyzed 75 relapsed/refractory and 71 treatment-naïve high-risk cases from prospective clinical trials by single nucleotide polymorphism arrays and targeted next-generation sequencing. Increased genomic complexity was a hallmark of relapsed/refractory and treatment-naïve high-risk CLL. In relapsed/refractory cases previously exposed to the selective pressure of chemo(immuno)therapy, gain(8)(q24.21) and del(9)(p21.3) were particularly enriched. Both alterations affect key regulators of cell-cycle progression, namely MYC and CDKN2A/B While homozygous CDKN2A/B loss has been directly associated with Richter transformation, we did not find this association for heterozygous loss of CDKN2A/B Gains in 8q24.21 were either focal gains in a MYC enhancer region or large gains affecting the MYC locus, but only the latter type was highly enriched in relapsed/refractory CLL (17%). In addition to a high frequency of NOTCH1 mutations (23%), we found recurrent genetic alterations in SPEN (4% mutated), RBPJ (8% deleted) and SNW1 (8% deleted), all affecting a protein complex that represses transcription of NOTCH1 target genes. We investigated the functional impact of these alterations on HES1, DTX1 and MYC gene transcription and found derepression of these NOTCH1 target genes particularly with SPEN mutations. In summary, we provide new insights into the genomic architecture of high-risk CLL, define novel recurrent DNA copy number alterations and refine knowledge on del(9p), gain(8q) and alterations affecting NOTCH1 signaling. This study was registered at ClinicalTrials.gov with number NCT01392079.
Keywords:Cell Cycle, Genomics, B-Cell Chronic Lymphocytic Leukemia, Mutation, Prospective Studies, Notch1 Receptor
Source:Haematologica
ISSN:0390-6078
Publisher:Ferrata Storti Foundation
Volume:105
Number:5
Page Range:1379-1390
Date:May 2020
Official Publication:https://doi.org/10.3324/haematol.2019.217307
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library